Co-Diagnostics Announces Proprietary AI Integration into Co-Dx Primer AI Platform

Co-Diagnostics (Co-Dx), a molecular diagnosis company, announced plans to integrate its proprietary artificial intelligence algorithms into the Co-Dx Primer AI Platform, designed to accelerate PCR diagnostics. The AI component will analyze genomic data to identify optimal primer and probe sequences, reducing design time and enhancing specificity. The integration aims to support diagnostic applications in infectious diseases, oncology and other molecular testing markets.

The move highlights the growing use of AI in molecular diagnostics. Co-Diagnostics’ proprietary integration targets low-cost, rapid test development in both clinical and field environments. The models will function together with the Co-Dx cloud platform and internal databases to form the foundation of Co-Dx Primer AI.

Posted by MedCloudInsider Editors on 11/04/2025